Abbott (NYSE:ABT) has received FDA emergency use authorization for a molecular test for novel coronavirus (COVID-19).
The company said yesterday that it will immediately ship 150,000 of its RealTime SARS-CoV-2 EUA tests to existing customers in the U.S. Customers can use the tests on Abbott’s m2000 RealTime system, and Abbott will deploy additional m2000 systems as needed.
The more than 175 m2000 systems in the U.S. are able to run up to 470 tests in 24 hours. Abbott has a goal of eventually providing up to 1 million coronavirus tests per week.
“A global challenge like coronavirus requires the commitment and cooperation of everyone who has the ability to help address it,” Abbott CEO Miles White said in a news release. “I’m proud of the Abbott team and what they’ve accomplished in such a short period of time, and I want to thank the administration and the FDA for their partnership in making this happen.”
Abbott is but one of a growing number of companies racing to develop and distribute tests for COVID-19 to laboratories amid the coronavirus pandemic.